Neurodegeneration with brain iron accumulation

Neurodegeneration with brain iron accumulation (NBIA), formerly known as Hallervorden-Spatz syndrome, is a group of rare inherited neurological disorders characterized by abnormal accumulation of iron in the basal ganglia, particularly the globus pallidus and substantia nigra. This iron deposition leads to progressive damage to the nervous system, resulting in movement disorders and cognitive decline. NBIA encompasses several distinct subtypes, including pantothenate kinase-associated neurodegeneration (PKAN, the most common form), PLA2G6-associated neurodegeneration (PLAN), mitochondrial membrane protein-associated neurodegeneration (MPAN), beta-propeller protein-associated neurodegeneration (BPAN), fatty acid hydroxylase-associated neurodegeneration (FAHN), and others. The hallmark clinical features of NBIA include progressive dystonia (sustained muscle contractions causing abnormal postures), spasticity, parkinsonism (rigidity, bradykinesia, and tremor), choreoathetosis, and cognitive deterioration. Many patients also develop dysarthria (difficulty speaking), dysphagia (difficulty swallowing), and visual impairment due to retinal degeneration or optic atrophy. Psychiatric symptoms including behavioral changes, personality alterations, and depression may also occur. Brain MRI characteristically shows the "eye-of-the-tiger" sign in PKAN, a pattern of hypointensity with a central hyperintense region in the globus pallidus on T2-weighted imaging. The age of onset and rate of progression vary considerably depending on the specific subtype. Classic PKAN typically presents in early childhood, while atypical forms may not manifest until adolescence or adulthood. Currently, there is no cure for NBIA. Treatment is symptomatic and supportive, including medications for dystonia (such as baclofen, trihexyphenidyl, and botulinum toxin injections), physical and occupational therapy, speech therapy, and nutritional support. Deep brain stimulation (DBS) has been used in some patients with variable results. Iron chelation therapy with deferiprone has been investigated in clinical trials, with some evidence suggesting it may slow disease progression, though definitive efficacy has not yet been established.

Common questions about Neurodegeneration with brain iron accumulation